Company Profile
Bio-Path Holdings Stock Price, News & Catalysts
- Ticker:
- BPTH
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.00 USD (+66.67%)
Close
Last updated: October 5, 2026
—
Market cap
Why the stock is moving
Current closing-price context is not available for BPTH.
Company overview
Antisense Oncology Company
Bio-Path Holdings develops liposomal antisense therapies for cancer. Its DNAbilize platform packages short DNA molecules in neutral lipid nanoparticles to reduce production of disease-driving proteins.
Prexigebersen in Acute Myeloid Leukemia
Prexigebersen, or BP1001, targets GRB2, an adaptor protein involved in cancer-cell signaling. The candidate is being studied with established leukemia therapies in patients with acute myeloid leukemia and related blood cancers.
BP1002 BCL-2 Program
BP1002 targets BCL-2, a protein that helps cancer cells evade programmed cell death. Clinical development focuses on relapsed or refractory acute myeloid leukemia and other hematologic malignancies.
BP1003 STAT3 Program
BP1003 is designed to reduce STAT3 expression, a signaling protein implicated in tumor growth, survival, and immune evasion. The program extends DNAbilize into solid tumors.
Future catalysts
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Bio-Path Holdings (BPTH)?
Bio-Path Holdings (BPTH) most recently closed at 0.00 USD, a +66.67% move versus the previous session.
What does Bio-Path Holdings do?
Antisense Oncology Company Bio-Path Holdings develops liposomal antisense therapies for cancer. Its DNAbilize platform packages short DNA molecules in neutral lipid nanoparticles to reduce production of disease-driving proteins. Prexigebersen in Acute Myeloid Leukemia Prexigebersen, or BP1001, targets GRB2, an adaptor protein involved in cancer-cell...
On which exchange is BPTH stock listed?
Bio-Path Holdings (BPTH) is associated with NASDAQ, United States, Biopharma.
What is BCL-2?
BP1002 BCL-2 Program BP1002 targets BCL-2, a protein that helps cancer cells evade programmed cell death.
Which conditions is Bio-Path Holdings targeting with BCL-2?
Bio-Path Holdings is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
What is Antisense?
Antisense Oncology Company Bio-Path Holdings develops liposomal antisense therapies for cancer.
What is Oncology?
Antisense Oncology Company Bio-Path Holdings develops liposomal antisense therapies for cancer.